Samrat Sanghvi, MD
Radiation Oncology · Casa Grande, AZNPI 1811422637
Payments from drug & device makers
What this record shows
49 manufacturers reported payments, led by Daiichi Sankyo Inc. at 26.2% of the total. 2025 is the largest year on record at $2,972, 2.2 times the $1,356 reported in 2022.
Across 178 payments — averaging $39.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Daiichi Sankyo Inc.$2K
- Johnson & Johnson$2K
- Novartis$571
- Merck$288
- AstraZeneca$273
- Pfizer$209
- plus $2K from 43 others
Across 2 payments — averaging $29,396 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$59K
What the payments were for
- Consulting fees$3,26247%
- Food & beverage$3,69053%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,951 in reported general payments places this provider in the 75th percentile of 138 radiation oncology providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lidocaine Hcl ViscousLidocaine Hcl | 30 | $337 |
| Morphine Sulfate ErMorphine Sulfate | 14 | $295 |
| Dexamethasone | 17 | $274 |
| Oxycodone Hcl | 18 | $154 |
| Lorazepam | 12 | $20 |
Paid to pharmacies, not to this prescriber.
Other radiation oncology in Casa Grande
- John KreslPhoenix$248K
- Eric GrossChandler$26K
- Carlos VargasScottsdale$22K
- Vershalee ShuklaScottsdale$19K
- Aaron AmbradScottsdale$18K
- Murali MurtyGlendale$17K
- Terence SioScottsdale$15K
- Sam SunGoodyear$14K
- Gordon GradoScottsdale$12K
- Tam NguyenMesa$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.